Setmelanotide in a Single Patient With Partial Lipodystrophy
Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
The objective of this single patient study is to assess the safety and efficacy of
setmelanotide as a treatment of severe metabolic abnormalities resulting from LD, especially
refractory hypertriglyceridemia leading to recurrent bouts of pancreatitis.